BackgroundChronic migraine is a disabling condition that is currently underdiagnosed and undertreated. In this narrative review, we discuss the future of chronic migraine management in relation to recent progress in evidence-based pharmacological treatment.FindingsPatients with chronic migraine require prophylactic therapy to reduce the frequency of migraine attacks, but the only currently available evidence-based prophylactic treatment options for chronic migraine are topiramate and onabotulinumtoxinA. Improved prophylactic therapy is needed to reduce the high burden of chronic migraine in Italy. Monoclonal antibodies that target the calcitonin gene-related peptide (CGRP) pathway of migraine pathogenesis have been specifically developed for the prophylactic treatment of chronic migraine. These anti-CGRP/R monoclonal antibodies have demonstrated good efficacy and excellent tolerability in phase II and III clinical trials, and offer new hope to patients who are currently not taking any prophylactic therapy or not benefitting from their current treatment.ConclusionsTreatment of chronic migraine is a dynamic and rapidly advancing area of research. New developments in this field have the potential to improve the diagnosis and provide more individualised treatments for this condition. Establishing a culture of prevention is essential for reducing the personal, social and economic burden of chronic migraine.

中文翻译：

---

当前和新兴的慢性偏头痛循证治疗方案：叙述性评论

背景慢性偏头痛是一种致残性疾病，目前诊断不足和治疗不足。在这篇叙述性综述中，我们讨论了与循证药物治疗的最新进展相关的慢性偏头痛管理的未来。 发现慢性偏头痛患者需要预防性治疗以减少偏头痛发作的频率，但目前唯一可用的循证预防性治疗慢性偏头痛的选择是托吡酯和肉毒杆菌毒素 A。需要改进预防性治疗以减轻意大利慢性偏头痛的高负担。针对偏头痛发病机制的降钙素基因相关肽 (CGRP) 通路的单克隆抗体已专门开发用于慢性偏头痛的预防性治疗。这些抗 CGRP/R 单克隆抗体在 II 期和 III 期临床试验中表现出良好的疗效和优异的耐受性，为目前未采取任何预防性治疗或未从目前治疗中受益的患者提供了新的希望。结论慢性偏头痛的治疗是一个动态且快速发展的研究领域。该领域的新发展有可能改善诊断并为这种情况提供更个性化的治疗。建立预防文化对于减轻慢性偏头痛的个人、社会和经济负担至关重要。结论慢性偏头痛的治疗是一个动态且快速发展的研究领域。该领域的新发展有可能改善诊断并为这种情况提供更个性化的治疗。建立预防文化对于减轻慢性偏头痛的个人、社会和经济负担至关重要。结论慢性偏头痛的治疗是一个动态且快速发展的研究领域。该领域的新发展有可能改善诊断并为这种情况提供更个性化的治疗。建立预防文化对于减轻慢性偏头痛的个人、社会和经济负担至关重要。